

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Reiner Laus et al.

Application No.: 10/666,122

Confirmation No.: 8703

Filed: September 19, 2003

Art Unit: 1643

For: IMMUNOTHERAPEUTIC COMPOSITIONS
AND METHODS FOR THE TREATMENT
OF MODERATELY TO WELL-
DIFFERENTIATED CANCERS

Examiner: L. A. Bristol

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark

Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: June 14, 2006

Respectfully submitted,

By Gary M. Myles
 Gary M. Myles, Ph.D.
 Registration No.: 46,209
DARBY & DARBY P.C.
 P.O. Box 5257
 New York, New York 10150-5257
 (206) 262-8900
 (212) 527-7701 (Fax)
 Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/666,122-Conf. #8703
				Filing Date	September 19, 2003
				First Named Inventor	Reiner Laus
				Art Unit	1643
				Examiner Name	L. A. Bristol
Sheet	1	of	1	Attorney Docket Number	20642/1203635-US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO 02/15915	02-28-2002	The Center for the Improvement of Human Functioning International, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Nestle et. al., "Vaccination of Melanoma Patients with Peptide- or Tumor Lysate - Pulsed Dendritic Cells," <i>Nature Medicine</i> , 4(3):328-332 (1998)	
	CB	Paglia et al., "Murine Dendritic Cells Loaded In Vitro with Soluble Protein Prima Cytotoxic T Lymphocytes Against Tumor Antigen In Vivo," <i>J. Exp. Med.</i> , 183:317-322 (1996)	
	CC	Zier, K. et al., "IFNgamma secretion following stimulation with total tumor peptides from autologous human tumors," <i>Journal of Immunological Methods</i> , 241(1-2):61-68 (2000)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

{S:\20642\1203635-us2\80066380.DOC [REDACTED]}

Examiner Signature		Date Considered	
--------------------	--	-----------------	--